THETA BRAINWAVE ANALYSIS WITH EEG
| PARTICIPANT INFORMATION | |||
|---|---|---|---|
| Identification: 0001 Gender: M Age: 23 |
Weight: 73 kg Height: 196 cm |
BMI: 19.00 | Start Date: 2025-03-03 |
| EEG ANALYSIS | ||||||
|---|---|---|---|---|---|---|
| Date | Mean score (uV) | Mean norm (uV) | Rate score (%) | Rate norm (%) | Rate analysis | |
| No Treatment | 2025-03-03 | 20.84 | 20 ~ 50 | 53 | 51 ~ 80 |  |
| Placebo Control (Blank) | 2025-03-04 | 15.04 | 20 ~ 50 | 45 | 51 ~ 80 |  |
| Mega Gold Treatment | 2025-03-05 | 46.43 | 20 ~ 50 | 78 | 51 ~ 80 |  |
| TRMX 5 50th Anniversary Treatment | 2025-03-06 | 33.40 | 20 ~ 50 | 72 | 51 ~ 80 | |
| Other Brand Treatment (No Sporolife) | 2025-03-07 | 5.70 | 20 ~ 50 | 8 | 51 ~ 80 | |
No Treatment | Placebo Control (Blank) | Mega Gold Treatment | TRMX 5 50th Anniversary Treatment | Other Brand Treatment (No Sporolife) |
 |
|
 |
|
PHYSICIAN SUMMARY - KEY FINDINGS |
|
The clinical evaluation of "Mega Gold Treatment" demonstrates its
effectiveness in promoting optimal sleep transition. It
achieved an A rating, with 78% theta wave activity within
the 51–80% range, and an average amplitude of 46.43 uV which falls within the normal range (20–50 uV). Conversely, "Other Brand Treatment (No Sporolife)" was associated with sleep disturbances, receiving an F rating due to only 8% theta wave activity, falling below the expected 51–80% range. Its average amplitude was 5.70 uV, significantly below the normal range (20–50 μV). These findings highlight the superior performance of Mega Gold Treatment across all five clinical evaluations. |